Lycia Therapeutics
PrivateLast Round
Series D
Jun 25, 2026
Total Funding Raised
$301.6M
Momentum Score
25 /100
Company Overview
Lycia Therapeutics is a biotechnology company focused on discovering and developing first-in-class therapeutics using a lysosomal targeting chimeras platform to degrade extracellular and membrane-bound proteins associated with challenging diseases like cancers and autoimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lycia Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Lycia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 25, 2026 | ||||
| Series C | May 13, 2024 | ||||
| Series B | Sep 9, 2021 | ||||
| Series A | Jun 9, 2020 |
Lycia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series B |
| Owl Rock Capital Group | Series C |
| Janus Henderson Group | Series C, Series D |
| Balyasny Asset Management L.P. | Series D |
| Franklin Advisers, Inc. | Series C |
| Franklin Templeton | Series D |
| TD Securities | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
$75M round led by Balyasny Asset Management and Janus Henderson.
- Feb 7, 2025
Chin Lee, M.D., M.P.H. appointed as new chief medical officer.
Lycia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Lycia Therapeutics's valuation, stock price, and market status.
